NLS Pharmaceutics (NLSP) News Today → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Free NLSP Stock Alerts $0.13 0.00 (0.00%) (As of 05:37 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offeringfinanznachrichten.de - March 22 at 7:12 PMNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platformfinanznachrichten.de - March 20 at 4:33 PMNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct Offeringfinanznachrichten.de - March 20 at 4:33 PMNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Eventfinanznachrichten.de - March 14 at 1:02 PMNLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliancefinanznachrichten.de - March 11 at 9:23 AMNasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliancefinance.yahoo.com - March 11 at 9:23 AMNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaqfinanznachrichten.de - February 23 at 8:59 AMNLSP NLS Pharmaceutics Ltd.seekingalpha.com - February 14 at 8:27 AMNotice of Deficiency with Nasdaq Continued Listing Requirementsfinance.yahoo.com - January 20 at 10:29 AMNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing Requirementsfinanznachrichten.de - January 12 at 7:41 PMNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider Tradesbenzinga.com - December 23 at 9:37 AMNLS Pharmaceutics Ltd Ordinary Sharesmorningstar.com - December 21 at 7:40 PMNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and Datesbenzinga.com - December 5 at 7:23 AMNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.finance.yahoo.com - December 1 at 8:10 AMNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomniafinanznachrichten.de - November 27 at 10:28 AMNLS Pharmaceutics Ltd Ordinary Shares NLSPmorningstar.com - November 21 at 8:26 PMWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% Todaymsn.com - November 16 at 1:11 PMNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loanfinance.yahoo.com - November 16 at 8:11 AMNLS Pharmaceuticals to Reschedule Company Update on Strategic Discussionsfinance.yahoo.com - October 19 at 5:52 PMNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic Partnershipsfinanznachrichten.de - October 12 at 1:16 PMNLS Pharmaceutics Announces Company Update on Strategic Partnershipsfinance.yahoo.com - October 12 at 1:16 PMNLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95msn.com - October 5 at 6:41 PMMaxim Group Downgrades NLS Pharmaceutics (NLSP)msn.com - September 14 at 5:40 PMNLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letterbenzinga.com - August 28 at 2:28 PMNLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocolfinance.yahoo.com - July 3 at 12:00 PMNLS Pharmaceutics AG: NLS Pharmaceutics Company Update and Webcast Today Postponedfinanznachrichten.de - July 2 at 9:49 AMNLS Pharmaceutics Releases the Results from its Annual General Meetingfinance.yahoo.com - June 30 at 8:27 PMNLS Pharmaceutics Company Update and Webcast Today Postponedfinance.yahoo.com - June 30 at 10:20 AMNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update Webcastfinanznachrichten.de - June 19 at 8:04 AMCORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vestfinance.yahoo.com - June 19 at 8:04 AMNLS Pharmaceutics (NLSP) Receives a Buy from Maxim Groupmarkets.businessinsider.com - June 15 at 5:00 PMNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vestfinanznachrichten.de - June 15 at 12:00 PMNLS Pharmaceutics Announces Company Update Webcastfinance.yahoo.com - June 15 at 12:00 PMNLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vestfinance.yahoo.com - June 15 at 12:00 PMNLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindolfinance.yahoo.com - June 14 at 10:22 AMNLS Pharmaceutics AG: NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officerfinanznachrichten.de - May 8 at 11:19 AMNLS Pharmaceutics appoints Keith Harrison Dewedoff as interim CFO; stock slumps ~13%msn.com - May 8 at 11:19 AMNLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officerfinance.yahoo.com - May 8 at 11:19 AMNLS Pharmaceutics AG: NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023finanznachrichten.de - May 4 at 10:31 AMAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Fate Therapeutics (FATE) and NLS Pharmaceutics (NLSP)markets.businessinsider.com - May 4 at 10:31 AMNLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023finance.yahoo.com - May 4 at 10:31 AMNLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsyfinance.yahoo.com - May 2 at 9:49 AMNLS Pharmaceutics AG: NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacologyfinanznachrichten.de - April 25 at 10:57 AMNLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacologyfinance.yahoo.com - April 25 at 10:57 AMWhy Did Bullfrog AI Stock Jump More Than 50%? (NLSP)marketbeat.com - April 5 at 7:01 AMMaxim Group Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)markets.businessinsider.com - March 28 at 7:14 PMNLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2finance.yahoo.com - March 27 at 9:40 AMNLS Pharmaceutics AG: NLS Pharmaceutics to Present at the 35th Annual Roth Conferencefinanznachrichten.de - March 1 at 8:55 AMNLS Pharmaceutics to Present at the 35th Annual Roth Conferencefinance.yahoo.com - March 1 at 8:55 AMMaxim Group Keeps Their Buy Rating on NLS Pharmaceutics (NLSP)markets.businessinsider.com - January 31 at 1:11 PM Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! NLSP Media Mentions By Week NLSP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLSP News Sentiment▼0.000.52▲Average Medical News Sentiment NLSP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLSP Articles This Week▼00▲NLSP Articles Average Week Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Context Therapeutics News Grifols News LAVA Therapeutics News Mainz Biomed News Pharvaris News Procaps Group News Qilian International Holding Group News Tiziana Life Sciences News Aclarion News Alpha Tau Medical News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLSP) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsSHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy SykesMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.